BAX Actualités Forex
Baxter International Boosts FY24 Outlook - Update
While reporting financial results for the second quarter on Tuesday, health care company Baxter International Inc. (BAX) raised its earnings, adjusted earnings and sales growth guidance for the full-year 2024. The company also provided outlook for the third quarter.
RTTNews
|
il y a 143
Baxter Int'l Names Proposed Kidney Care Spinoff As Vantive
Medtech firm Baxter International Inc. (BAX) announced Tuesday that Vantive will be the name of the company's proposed spinoff of its Renal Care and Acute Therapies businesses.
RTTNews
|
il y a 521
Baxter Int'l Launches PERCLOT Absorbable Hemostatic Powder In The US
Baxter International Inc. (BAX) announced Monday the launch of PERCLOT Absorbable Hemostatic Powder in the U.S. PERCLOT is a passive, absorbable hemostatic powder that is ready to use and designed for patients with intact coagulation to address mild bleeding.
RTTNews
|
il y a 522
Baxter International Q1 Results Top Estimates; Boosts FY23 Adj. EPS Outlook
Health care company Baxter International Inc. (BAX) reported Thursday that net income attributable to Baxter for the first quarter declined to $44 million or $0.09 per share from $71 million or $0.14 per share in the prior-year quarter. Excluding items, adjusted earnings for the quarter were $0.59 per share, compared to $0.93 per share in the year-ago quarter.
RTTNews
|
il y a 610
Baxter Int'l Announces US Launch Of ZOSYN Premix
Medtech firm Baxter International Inc. (BAX) announced Tuesday the U.S. launch of ZOSYN (piperacillin and tazobactam) Injection. Zosyn premix is indicated for the treatment of multiple infections caused by susceptible bacteria and is available in Baxter's proprietary single-dose Galaxy containers.
RTTNews
|
il y a 633
Baxter International Guides Q1, FY23 Adj. EPS Well Below Estimates; To Cut 5% Jobs - Update
While reporting financial results for the fourth quarter on Thursday, health care company Baxter International Inc. (BAX) initiated earnings, adjusted earnings and sales growth guidance for the first quarter and for the full-year 2023.
The company said the guidance for 2023 reflects a challenging first half of the year due to increased cost of sales resulting from elevated costs of inventory produced in the second half of 2022, reflecting the significant inflationary pressures the company experienced, that will impact earnings when the related inventory is sold in 2023. Baxter expects the impact from these inflationary pressures on its earnings to begin to ease in the second half of the year.
RTTNews
|
il y a 687
Baxter International Again Slashes FY22 Outlook - Update
While reporting financial results for the second quarter on Thursday, health care company Baxter International Inc. (BAX) again lowered its earnings, adjusted earnings and sales growth for the full-year 2022. The company also provided outlook for the third quarter.
RTTNews
|
il y a 883
